Cargando…

n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease

DNA telomere shortening associates with the age-related increase cardiovascular disease (CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10 (CoQ) on te...

Descripción completa

Detalles Bibliográficos
Autores principales: Barden, Anne, O’Callaghan, Nathan, Burke, Valerie, Mas, Emile, Beilin, Lawrence J., Fenech, Michael, Irish, Ashley B., Watts, Gerald F., Puddey, Ian B., Huang, Rae-Chi, Mori, Trevor A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808901/
https://www.ncbi.nlm.nih.gov/pubmed/27007392
http://dx.doi.org/10.3390/nu8030175
_version_ 1782423549135290368
author Barden, Anne
O’Callaghan, Nathan
Burke, Valerie
Mas, Emile
Beilin, Lawrence J.
Fenech, Michael
Irish, Ashley B.
Watts, Gerald F.
Puddey, Ian B.
Huang, Rae-Chi
Mori, Trevor A.
author_facet Barden, Anne
O’Callaghan, Nathan
Burke, Valerie
Mas, Emile
Beilin, Lawrence J.
Fenech, Michael
Irish, Ashley B.
Watts, Gerald F.
Puddey, Ian B.
Huang, Rae-Chi
Mori, Trevor A.
author_sort Barden, Anne
collection PubMed
description DNA telomere shortening associates with the age-related increase cardiovascular disease (CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10 (CoQ) on telomere length was studied in a double-blind placebo-controlled trial in CKD. Eighty-five CKD patients were randomized to: n-3 fatty acids (4 g); CoQ (200 mg); both supplements; or control (4 g olive oil), daily for 8 weeks. Telomere length was measured in neutrophils and peripheral blood mononuclear cells (PBMC) at baseline and 8 weeks, with and without correction for cell counts. Main and interactive effects of n-3 fatty acids and CoQ on telomere length were assessed adjusting for baseline values. F(2)-isoprostanes were measured as markers of oxidative stress. There was no effect of n-3 fatty acids or CoQ on neutrophil or PBMC telomere length. However, telomere length corrected for neutrophil count was increased after n-3 fatty acids (p = 0.015). Post-intervention plasma F(2)-isoprostanes were negative predictors of post-intervention telomere length corrected for neutrophil count (p = 0.025).The effect of n-3 fatty acids to increased telomere length corrected for neutrophil count may relate to reduced oxidative stress and increased clearance of neutrophils with shorter telomeres from the circulation. This may be a novel mechanism of modifying CVD risk in CKD patients.
format Online
Article
Text
id pubmed-4808901
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48089012016-04-04 n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease Barden, Anne O’Callaghan, Nathan Burke, Valerie Mas, Emile Beilin, Lawrence J. Fenech, Michael Irish, Ashley B. Watts, Gerald F. Puddey, Ian B. Huang, Rae-Chi Mori, Trevor A. Nutrients Article DNA telomere shortening associates with the age-related increase cardiovascular disease (CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10 (CoQ) on telomere length was studied in a double-blind placebo-controlled trial in CKD. Eighty-five CKD patients were randomized to: n-3 fatty acids (4 g); CoQ (200 mg); both supplements; or control (4 g olive oil), daily for 8 weeks. Telomere length was measured in neutrophils and peripheral blood mononuclear cells (PBMC) at baseline and 8 weeks, with and without correction for cell counts. Main and interactive effects of n-3 fatty acids and CoQ on telomere length were assessed adjusting for baseline values. F(2)-isoprostanes were measured as markers of oxidative stress. There was no effect of n-3 fatty acids or CoQ on neutrophil or PBMC telomere length. However, telomere length corrected for neutrophil count was increased after n-3 fatty acids (p = 0.015). Post-intervention plasma F(2)-isoprostanes were negative predictors of post-intervention telomere length corrected for neutrophil count (p = 0.025).The effect of n-3 fatty acids to increased telomere length corrected for neutrophil count may relate to reduced oxidative stress and increased clearance of neutrophils with shorter telomeres from the circulation. This may be a novel mechanism of modifying CVD risk in CKD patients. MDPI 2016-03-19 /pmc/articles/PMC4808901/ /pubmed/27007392 http://dx.doi.org/10.3390/nu8030175 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barden, Anne
O’Callaghan, Nathan
Burke, Valerie
Mas, Emile
Beilin, Lawrence J.
Fenech, Michael
Irish, Ashley B.
Watts, Gerald F.
Puddey, Ian B.
Huang, Rae-Chi
Mori, Trevor A.
n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
title n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
title_full n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
title_fullStr n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
title_full_unstemmed n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
title_short n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
title_sort n-3 fatty acid supplementation and leukocyte telomere length in patients with chronic kidney disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808901/
https://www.ncbi.nlm.nih.gov/pubmed/27007392
http://dx.doi.org/10.3390/nu8030175
work_keys_str_mv AT bardenanne n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT ocallaghannathan n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT burkevalerie n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT masemile n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT beilinlawrencej n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT fenechmichael n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT irishashleyb n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT wattsgeraldf n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT puddeyianb n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT huangraechi n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease
AT moritrevora n3fattyacidsupplementationandleukocytetelomerelengthinpatientswithchronickidneydisease